Anti-CD19 CAR-T cytotherapy was incapable of demonstrating good efficiency to eliminate myeloma cells though it performs excellent in treating ALL or other hematologic malignancy in consideration of lower expression of CD19 in myeloma cells' surface 28. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.